Hints and tips:
...Read the full story, from the FT’s Bryan Harris and Michael Stott in Brazil, here....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Of those received, 5.7m were the BioNTech/Pfizer jab; 3.6m were AstraZeneca; 4m were Sinovac of China and 900,000 were Russia’s Sputnik V, coronavirus tsar Hugo López-Gatell told the news conference....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Surveys conducted by The Harris Poll found that approval of the pharmaceutical industry had almost doubled from 32 per cent in January last year to 62 per cent in February this year....
...Brazil’s health regulator on Saturday requested further data on Russia’s Sputnik V vaccine, after finding that minimum requirements had not been met in an application for emergency use submitted by a local...
...A version of this article was first published by Nikkei Asia on October 19 2021. ©2021 Nikkei Inc. All rights reserved....
...Now, with the rollout of the Oxford/AstraZeneca vaccine temporarily suspended, the government has switched its attention to J&J and Pfizer....
...Additional reporting by Bryan Harris in Sao Paulo and Guy Chazan in Berlin...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Greene has also worked on many complex M&A deals, including pharmaceutical company Mylan’s pending $50bn combination with Upjohn, a division of Pfizer....
...(WaPo) Wagering on a winner Wall Street donors are fawning over three Democratic candidates — Joe Biden, Kamala Harris and Pete Buttigieg....
...The six chief executives from Merck, Pfizer, AstraZeneca, AbbVie, Sanofi, and Bristol-Myers Squibb, plus an executive president from Johnson & Johnson, will face tough questions on Tuesday on what is fast...
...That would help fund an acquisition of Pfizer or Merck’s consumer health businesses, currently under review by those groups....
...(FT) Valeant — the harder they fall Two years ago executives from Pfizer, the world’s second-largest pharmaceuticals group, sat down for dinner with their counterparts at Valeant and raised the prospect...
...(The Atlantic) London skyline 1616 v 2016 Juxtaposed images sketched 400 years apart show the change in the city’s skyline from the banks of the Thames. (The Guardian)...
...(FT) Scientists v conspiracists The European Organization for Nuclear Research, or Cern, is gearing up for another run at smashing particles together to unlock the secrets of the universe....
...(FT) Murdoch v Trump: Fox and The Hair Donald Trump has gone to war with an unlikely enemy....
...The Takeover Code makes it tough for Pfizer to raise its offer before a Monday deadline for a formal bid....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“These higher-priced companies are a better reflection of the American economy,” said Jack Ablin, chief investment officer at Harris Private Bank....
...Chris Harris, its chairman, is a former employee of Jones Lang Wootton....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...… Missed goal Has Seymour Pierce chairman Keith Harris lost his touch?...
International Edition